Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prana’s COO Diane Angus, Head Of Research Robert Cherny On Prana’s Unique Mechanism Of Action In Neurodegenerative Drug Development: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Established in 1997, Melbourne, Australia-based biotech company Prana has developed a library of chemical compounds that addresses the role of biological metals in human disease. The company's lead compound PB2 in Alzheimer's disease completed Phase IIa clinical trials, and the company recently announced a preclinical candidate for Parkinson's disease. "Prana" is Sanskrit for "moving force," or "life force," which sustains life and diminishes as humans age. The company has formed its business strategy on neurological disorders that result from interactions between selected metals and target proteins as the brain ages. COO Diane Angus and Head of Research Robert Cherny sat down with PharmAsia News in Australia to talk about Prana's unique approach to developing compounds in the neurodegenerative space.

You may also be interested in...



Australia’s Prana Misses Primary Endpoint In POC Alzheimer’s Disease Trial; Stock Tanks

Prana’s lead Alzheimer’s candidate fails both primary and secondary endpoints in Alzheimer’s proof-of-concept- trial, but the company still has hopes that an extension study will show a stronger signal.

Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial

The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.

Aussie Biotech Prana’s COO Diane Angus On Aging and Neurodegenerative Development In Alzheimer’s Space: An Interview With PharmAsia News (Part 1 of 2)

Established in 1997, Melbourne, Australia-based biotech company Prana has developed a library of chemical compounds that addresses the role of biological metals in human disease. The company's lead compound PB2 in Alzheimer's disease completed Phase IIa clinical trials, and the company recently announced a preclinical candidate for Parkinson's disease. "Prana" is Sanskrit for "moving force," or "life force," which sustains life and diminishes as humans age. The company has formed its business strategy on neurological disorders that result from interactions between selected metals and target proteins as the brain ages. COO Diane Angus sat down with PharmAsia News in Australia to talk about Prana's unique approach to developing compounds in the neurodegenerative space.

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel